profit from every $100 of sales.
$0$100
Pulmonx
$2.80+9.38% today
+45.8% in 1 year
1-year low $1.171-year high $3.16
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Pulmonx sold, what it kept, and what it did with the cash.
Sales went from $53.7 million in 2022 to $90.5 million in 2025, with -$54.0 million of profit last year.
SalesProfit
Pulmonx vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Pulmonx | No profit yet | ||
 Boston Scientific | 22.0× · Fair price | ||
 Koninklijke Philips | 30.0× · Fair price | ||
 Steris | 31.9× · Expensive | ||
 Zimmer Biomet Holdings | 29.1× · Fair price |
AI analysis
An AI analyst reads Pulmonx's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 54 | 69 | 84 | 90 | |
| 40 | 51 | 62 | 67 | |
| -59 | -62 | -58 | -54 | |
| -56 | -55 | -51 | -49 | |
| -59 | -61 | -56 | -54 | |
| -1.59 | -1.60 | -1.44 | -1.33 | |
| 74.3% | 73.9% | 74.0% | 74.2% | |
| -109.3% | -90.2% | -68.9% | -59.3% | |
| -109.8% | -88.6% | -67.3% | -59.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 194 | 178 | 163 | 129 |
| Cash | 102 | 84 | 71 | 70 |
| Total debt | 24 | 41 | 56 | 56 |
| Total liabilities | 40 | 59 | 77 | 75 |
| 154 | 118 | 86 | 54 | |
| 37 | 38 | 39 | 41 | |
| -25.5% | -28.2% | -29.1% | -35.9% | |
| -38.3% | -51.4% | -65.7% | -99.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -45 | -38 | -32 | -32 | |
| 1 | 1 | 1 | 0 | |
| -46 | -38 | -33 | -33 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 16 | 22 | 23 | 21 |
Valuation
- –
- –
- –
- 1.2×
- 1.3×
- –
- –
- -26.9%
- -44.3%
- 0.0%
Profitability
- 74.2%
- -59.3%
- -59.7%
- -55.7%
- -50.8%
- -36.4%
- -92.9%
- -44.4%
- -51.5%
- 22.2%
Growth
- +19.0%
- –
- +0.3%
- –
- +3.0%
Financial health
- -0.3×
- 1.23
- 46.9%
- -15.5×
- 4.91
- 4.04
- 0.74
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 7%of 948
Bottom 7%of 871
Top 30%of 868
Bottom 2%of 985
What analysts expect
- Average price target
- $10.00
- Range
- $2.50 – $20.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 29, 2026 | -0.33 | -0.33 | +0.0% |
| Mar 4, 2026 | -0.25 | -0.39 | +35.9% |
| Nov 12, 2025 | -0.34 | -0.40 | +15.0% |
| Jul 30, 2025 | -0.38 | -0.40 | +5.0% |
| Apr 30, 2025 | -0.36 | -0.37 | +2.7% |
| Feb 19, 2025 | -0.33 | -0.45 | +26.7% |
| Oct 30, 2024 | -0.36 | -0.43 | +16.3% |
| Jul 31, 2024 | -0.39 | -0.41 | +4.9% |
News
Innovent reports cancer drug results in breast, lung, pancreatic tumorsSeeking Alpha · Oct 26, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
35No pass
Benjamin Graham
56No pass
Philip Fisher
48No pass
Peter Lynch
49No pass
Joel Greenblatt
0No pass
Charlie Munger
29No pass
Terry Smith
34No pass
Questions about Pulmonx
Is Pulmonx a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Pulmonx AI analysis
What does Pulmonx do?
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It is in Medical - Devices.
Does Pulmonx pay a dividend?
No. Pulmonx does not pay a dividend at the moment.
Is Pulmonx stock halal?
No. Pulmonx does not pass our halal screen: its debt is 46% of its market value, at or above the 33% limit. How we check
How has Pulmonx stock done over the past year?
Up 45.8% over the past twelve months, to $2.80. It traded between $1.17 and $3.16 and is 11.5% below its high.
Who are Pulmonx's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Pulmonx's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.